Intraocular drug delivery and filter device and methods of using same

Patent metadata

Field	Value
Publication number	US-2016193391-A1
Application number	US-201414916659-A
Country	US
Kind code	A1
Filing date	Sep 8, 2014
Priority date	Sep 6, 2013
Publication date	Jul 7, 2016
Grant date	—

Abstract

The present disclosure provides an implantable device comprising a substrate capable of capturing an intraocular target molecule and to methods of use thereof.

First claim

I/We claim:

1 . An implantable device comprising a substrate capable of capturing an intraocular target molecule.

2 . The implantable device of claim 1 , wherein the substrate comprises one or more of hydroxyapatite, a ceramic, tricalcium phosphate, bioglass, bone, calcium phosphate, metallic alloys, or a combination thereof.

3 . The implantable device of claim 1 or claim 2 , wherein the substrate comprises hydroxyapatite.

4 . The implantable device of claim 1 or claim 2 , wherein the substrate comprises a ceramic.

5 . The implantable device of any one of claims 1 , 2 or 4 , wherein the ceramic comprises mesoporous hydroxyapatite (MHA).

6 . The implantable device of any one of claims 1 - 5 , wherein the substrate is a solid, a porous matrix, a gel, a sheet, a membrane, a colloid, a microparticle, a nanoparticle, or does not include a polyethylene glycol-conjugated oligonucleotide.

7 . The implantable device of any one of claims 1 - 6 , wherein the device is capable of being implanted through an incision.

8 . The implantable device of any one of claims 1 - 6 , wherein the device is capable of being implanted by injection.

9 . The implantable device of any one of claims 1 - 8 , wherein the target molecule is a protein.

10 . The implantable device of any one of claims 1 - 9 , wherein the target molecule is an angiogenic compound.

11 . The implantable device of claim 10 , wherein the angiogenic compound comprises vascular endothelial growth factor (VEGF).

12 . The implantable device of claim 11 , wherein the angiogenic compound comprises VEGF 165 .

13 . The implantable device of any one of claims 1 - 12 , wherein the target molecule comprises an angiogenic compound but not ranibizumab, bevacizumab or pegaptanib.

14 . The implantable device of any one of claims 1 - 13 , wherein the device is capable of being regenerated in situ.

15 . The implantable device of claim 14 , wherein the device has a higher affinity for the target molecule compared to a corresponding thermally denatured target molecule.

16 . An implantable device comprising a substrate comprising one or more of hydroxyapatite and a ceramic, and a captured angiogenic compound.

17 . The implantable device of claim 16 , wherein the device is capable of releasing the captured angiogenic compound after exposure to a laser.

18 . The implantable device of claim 17 , wherein the device is capable of capturing the angiogenic compound after exposure to the laser.

19 . The implantable device of any one of claims 15 - 18 , wherein the angiogenic compound comprises VEGF from vitreous fluid of a subject.

20 . The implantable device of claim 19 , wherein the angiogenic compound comprises VEGF 165 .

21 . A method of treating an ocular disorder in a subject, the method comprising
implanting into an eye of the subject, and in contact with a tissue, cavity and/or fluid of the eye, a device comprising a substrate capable of capturing a target molecule present in the eye; and capturing the target molecule from the eye.

22 . The method of claim 20 or claim 21 , wherein the substrate comprises hydroxyapatite and/or a ceramic.

23 . The method of claim 22 , wherein the substrate comprises a ceramic.

24 . The method of claim 22 , wherein the ceramic comprises mesoporous hydroxyapatite (MHA).

25 . The method of any one of claims 20 - 24 , wherein the substrate does not include a polyethylene glycol-conjugated oligonucleotide.

26 . The method of any one of claims 20 - 25 , wherein the device is implanted through an incision in the eye.

27 . The method of any one of claims 20 - 25 , wherein the device is implanted by injecting the device into or through tissue of the eye.

28 . The method of any one of claims 20 - 27 , wherein the target molecule is an angiogenic compound.

29 . The method of claim 28 , wherein the angiogenic compound comprises vascular endothelial growth factor (VEGF).

30 . The method of claim 29 , wherein the angiogenic compound comprises VEGF 165 .

31 . The method of any one of claims 20 - 30 , wherein the target molecule comprises an angiogenic compound but not ranibizumab, bevacizumab or pegaptanib.

32 . The method of any one of claims 20 - 31 , the method further comprising, after capturing the target molecule from the eye, regenerating the device in situ.

33 . The method of claim 32 , wherein the step of regenerating the device comprises exposing the device to light from a laser or to a source capable of inducing a thermal reaction.

34 . The method of claim 33 , wherein the laser is an argon laser, a diode, a femtosecond laser, a Nd:Yag laser, a photodynamic laser, or a photodisruptive laser.

35 . The method of any one of claims 32 - 34 further comprising, after regenerating the device in situ, capturing the target molecule from the eye.

36 . The method of any one of claims 20 - 35 , wherein the ocular disorder is selected from the group consisting of macular degeneration (e.g., exudative age-related macular degeneration), bull's eye maculopathy, central serous retinopathy, chorioretinal scars, chorioretinitis, chorioretinitis, chorioretinitis, chorioretinitis, chorioretinitis from toxoplasma, chorioretinitis from tuberculous, choroid, choroidal (central areolar, choroidal atrophy, choroidal degeneration, choroidal detachment, choroidal haemorrhage, choroidal haemorrhage and rupture, choroidal neovascularization, choroidal sclerosis, choroideremia, choroiditis, choroiditis, choroiditis, detachment of retinal pigment epithelium, diabetic retinopathy, dystrophy, epiretinal membrane, generalized, gyrate atrophy, Harada's disease, hereditary choroidal dystrophy, diabetic macular edema, cystoid macular edema, hereditary retinal dystrophy, hypertensive retinopathy, macula scars of posterior pole (postinflammatory or post-traumatic), macular edema, or peripapillary, pars planitis, papillitis, peripheral retinal degeneration, posterior cyclitis, retinal detachment, retinal haemorrhage, retinal neovascularization, retinal vascular occlusions, retinitis, retinitis, retinitis, retinitis pigmentosa, retinochoroiditis, retinochoroiditis, retinochoroiditis, retinopathy, retinopathy of prematurity, retinoschisis, separation of retinal layers, solar retinopathy, and syphilitic chorioretinitis.

37 . The implantable device of any one of claims 1 - 19 , wherein the device further comprises an indicator portion configured to provide a practitioner information about a component, feature or recommended use of the device.

38 . The method of any one of claims 20 - 36 , wherein the device further comprises an indicator portion configured to provide a practitioner information about a component, feature or recommended use of the device.

Assignees

• Olson Jeffrey
• Univ Colorado Regents

Inventors

• Olson Jeffrey

Classifications

• A61K9/0051 Primary

  Ocular inserts or implants · CPC title

• A61F9/0017

  implantable in, or in contact with, the eye, e.g. ocular inserts · CPC title

• A61L31/16

  Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)} · CPC title

• A61L31/026 Primary

  Ceramic or ceramic-like structures, e.g. glasses · CPC title

• A61K41/0028

  Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds · CPC title